Ilya Rachman
Chief Executive Officer at IMMIX BIOPHARMA, INC.
Net worth: 2 M $ as of 2024-04-29
Ilya Rachman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMIX BIOPHARMA, INC. | Chief Executive Officer | 2011-12-31 | - |
| Chairman | 2011-12-31 | - | |
| Founder | 2011-12-31 | - | |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Chairman | - | - |
Career history of Ilya Rachman
Training of Ilya Rachman
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
| University of California, Los Angeles | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Chairman | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Stock Market
- Insiders
- Ilya Rachman
- Experience
